As a result, combination therapies could increase CD3+CD8+T cells, inhibit tumor proliferation and prevent tumor metastasis, providing a promising strategy to enhance immune-checkpoint inhibitor efficacy and the antitumor immunity of highly metastatic tumors. The gene discussed is CD8A; the disease is neoplasm.